Surgical management of acute pancreatitis in Italy: lessons from a prospective multicentre study

De, P.; Zerbi, Alessandro; Castoldi, Laura; Bassi, Claudio; Frulloni, Luca; Uomo, Generoso; Gabbrielli, Armando; Pezzilli, Raffaele; Cavallini, Giorgio

doi:10.1111/j.1477-2574.2010.00201.x

Cited by 23 publications

(15 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…<Comment > The mortality rate of necrotizing pancreatitis is significantly high from necrosectomy in the early phases and thus it is recommended to perform necrosectomy after at least 4 weeks after the onset of acute pancreatitis when necrosis has been sufficiently walled off . When infectious necrotizing pancreatitis is suspected, postponing intervention treatment is recommended until 4 weeks after onset when ANC becomes WON.…”

Section: Resultsmentioning

confidence: 99%

Japanese guidelines for the management of acute pancreatitis: Japanese Guidelines 2015

Yokoe

Takada

Mayumi

et al. 2015

J Hepato Biliary Pancreat

359

390

View full text Add to dashboard Cite

The JPN Guidelines 2015 were prepared using the most up-to-date methods, and including the latest recommended medical treatments, and we are confident that this will make them easy for many clinicians to use, and will provide a useful tool in the decision-making process for the treatment of patients, and optimal medical support. The free mobile application and calculator for the JPN Guidelines 2015 is available via http://www.jshbps.jp/en/guideline/jpn-guideline2015.html.

show abstract

Section: Resultsmentioning

confidence: 99%

Japanese guidelines for the management of acute pancreatitis: Japanese Guidelines 2015

Yokoe

Takada

Mayumi

et al. 2015

J Hepato Biliary Pancreat

359

390

View full text Add to dashboard Cite

show abstract

“…Six18–24 (reported in seven publications) of the 19 included studies were US based. Of the 13 EU-5 studies, five3 25–28 were conducted in the UK, three each in Germany29–31 and Italy,32–34 and one each in France35 and Spain 36. Overall, most studies were of a retrospective design (13 studies),3 21–23 25–33 were based on single-centre hospitals (13)18–22 24–26 28 29 31 33 35 36 and were principally tertiary referral units for which the reporting was exclusively on patients with SAP (10) 22 23 25–31 33.…”

Section: Resultsmentioning

confidence: 99%

Moderately severe and severe acute pancreatitis : a systematic review of the outcomes in the USA and European Union-5

Sarri¹,

Guo²,

Iheanacho³

et al. 2019

BMJ Open Gastroenterol

View full text Add to dashboard Cite

Background and objectivesThe global incidence of hospitalisation due to acute pancreatitis (AP) has been rising in the recent decades. In the USA alone, there was a 13.2% increase between 2009 and 2012 compared with 2002–2005. There remains a lack of approved treatments to prevent disease progression, leaving many liable to developing complications that include multisystem organ failure (OF) and death. This therapeutic deficit raises questions about the scale of the current burden of illness (BOI) associated with severe forms of AP. The aim of the systematic literature review (SLR) was to assess clinical, humanistic, and economic outcomes associated with moderately severe AP (MSAP) and severe AP (SAP) in the USA and the European Union-5 (EU-5).MethodsSystematic searches were conducted in MEDLINE and Embase to identify studies published in English (between 2007 and 2017) that reported on the BOI of MSAP and/or SAP. Manual searches of ‘grey’ literature sources were also conducted.ResultsThe SLR identified 19 studies which indicated that 15%–20% of patients with AP progress to more severe forms of the disease, up to 10.5% of those with SAP require surgery for complications, and up to 40% die during hospitalisation. By contrast, there appears to be a lack of data on the extent to which SAP affects patients’ quality of life.ConclusionThe available evidence clearly demonstrates that the current management for MSAP and SAP in the USA and EU-5 does not adequately meet patients’ needs. Early identification and intervention for AP is crucial, given the evidence of high rates of morbidity and an associated economic burden that is considerable. Since many patients with the condition present to hospitals at a point when multisystem OF or death is highly likely, there is a particularly urgent need for effective treatment options to prevent disease progression.

show abstract

“…Depending on how the previously mentioned duct opens into the duodenum four distinct types can be faund: In type I the annular duct opens itself normally into Wirsung's duct; in type II the annular duct opens itself into the common bile duct, in type III in the annular duct opens itself into the common bile duct and the duct of Wirsung is missing; in type IV in the annular duct opens itself into Santorini's duct [10,11].…”

Section: Discussionmentioning

confidence: 98%

“Ductal adenocarcinoma in anular pancreas”

Benassai

Perrotta

Furino

et al. 2015

International Journal of Surgery

View full text Add to dashboard Cite

Annular pancreas is an uncommon congenital anomaly which usually presents itself in infants and newborn. Rarely it can present in late adult life with wide range of clinical severities thereby making its diagnosis difficult. Pre-operative diagnosis is often difficult. CT scan can illustrate the pancreatic tissue encircling the duodenum. ERCP and MRCP are useful in outlining the annular pancreatic duct. Surgery still remains necessary to confirm diagnosis and bypassing the obstructed segment.

show abstract

Surgical management of acute pancreatitis in Italy: lessons from a prospective multicentre study

Cited by 23 publications

References 33 publications

Japanese guidelines for the management of acute pancreatitis: Japanese Guidelines 2015

Japanese guidelines for the management of acute pancreatitis: Japanese Guidelines 2015

Moderately severe and severe acute pancreatitis : a systematic review of the outcomes in the USA and European Union-5

“Ductal adenocarcinoma in anular pancreas”

Contact Info

Product

Resources

About